Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective treatment for malignant hematological diseases.1–3 The process begins with G-CSF treatment of donors which mobilizes the bone marrow stem cells into the peripheral blood.4–8 However, acute graft-versus-host-disease (aGVHD) remains a major life-threatening complication after allo-HSCT even when human leukocyte antigens (HLA) genotype matching is identical or haploidentical. This evidence concerns the gene CSF3 and graft versus host disease.